Sun Pharmaceutical Industries Ltd. — Capital/Financing Update 2020

Mar 17, 2020

Sun Pharmaceutical Industries Ltd .

Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai- 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91 -22) 4324 4343 Website : www.sunpharma.com CIN: L24230GJ1993PLC019050

March 17, 2020

To, BSE Limited, Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 00 I, Maharashtra, India.

National Stock Exchange of lndia Limited, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 , Maharashtra, India.

Scrip Code: 524 715

Symbol: SUNPHARMA

Dear Sir/Madam,

Subject: Outcome of Board Meeting pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("Listing Regulations"). ·

Further to our intimation dated March 12, 2020 and in terms of Regulation 30 of the Listing Regulations, we wish to inform you that:

• I. The Board of Directors of the Company, at its meeting held today i.e. March 17, 2020, has, inter alia, approved the buy-back by the Co.mpany of its equity shares of face value of Re. I/- each ("Equity Shares") from the Open Market through stock exchange mechanism as prescribed under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 ("Buy-back Regulations") at a maximum price of Rs. 425/- (Rupees Four Hundred Twenty Five Only) per Equity Share ("Maximum Buy-back Price") payable in cash, for an aggregate maximum amount of up to Rs. 1700,00,00,000/- (Rupees One Thousand Seven Hundred Crores Only) excluding transaction costs viz. brokerage, advisor's fees, intermediaries fees, public announcement publication fees, filing fees, turnover charges, applicable taxes such dS securities transaction tax, goods and services tax, income tax, stamp duty and other incidental and related expenses ("Transaction Costs") ("Maximum Buy-back Size"), which represents 9 .83% and 4.44% of the total paid-up Equity Share capital and free reserves (including Securities Premium Account) as per the latest audited standalone financial statements and audited consolidated financial statements, respectively of the Company for the financial year ended March 3 I, 2019, from the equity shareholders/beneficial owners of Equity Shares of the Company, except Promoter(s), members of Promoter Group and Persons acting in concert (" Buy-back").
• 1. At the Maximum Buy-back Size and the Maximum Buy-back Price, the indicative maximum number of Equity Shares to be bought back under the Buy-back would be 4,00,00,000 (Four Crores) Equity Shares which represents 1.67% of the total number of Equity Shares of the Company. However, the actual number of Equity Shares to be bought back during the Buy-back will depend upon the actual price paid (excluding the Transaction Costs) for the Equity Shares bought back and the aggregate actual amount utilised in the Buy-back.
• 1. The public announcement setting out the process, timelines and other requisite details will be released in due course in accordance with the Buy-back Regulations.

Y,~e lof3 Registered Office : SPARC, Tandalja, Vadodara - 390 012, Gujarat, INDIA.

Sun Pharmaceutical Industries Ltd. Sun House. Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai- 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website : www.sunpharma.com CIN : L24230GJ 1993PLC019050

1. The pre and post Buy-back shareholding pattern of the Company as on March 13, 2020, is enclosed hereto as Annexure- A.

The Board Meeting commenced at 12:00 p.m. and concluded at 0 I :25 p.m.

Request you to kindly take this on record and disseminate the same.

For Sun Pharmaceutical Industries Limited,

JW_

Ashok I. Bhuta Compliance Officer

Enclosed: As stated above.

Sun Pharmaceutical Industries Ltd. Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai- 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website : www.sunpharma.com CIN : L24230GJ1993PLC019050

Annexure- A

Category of Shareholder	Pre Bu -back		-back# Post Bu
	Number of equity share held	% to the existing equity share capital	Number of equity share held	%to the existing equity share capital
(A) Promote r and Promoter Group	131,21,34,535	54.69	1,31,21 ,34,535	55.61
(B) Public Shareholders
Institutions	78,15,76,801	32.57
Central Government I State	6,430	0.00
Government(s) I President of fndia			104,72,00,435	44.39
Non-fnstitutions	30,56, 17,204	12.74
Sub-Total	108,72,00,435	45.31
_(C) Non Promoter- Non Public	Nil	Nil	Nil	Nil
Tota l	239,93,34,970	100.00	235,93,34,970	100.00

Shareholding Pattern of the Company as on March 13, 2020

" Assuming the full utilisation of the Buy-back Size at the Maximum Buy-back Price. However, the post Buy-back, issued, subscribed and paid-up share capital may differ depending upon the actual number of Equity Shares bought back.

For Sun Pharmaceutical Industries Limited,

Ashok I. Bhuta Compliance Officer